Similarly, decreased NK cell cytotoxicity in patients with acute or chronic myeloid leukemia (AML or CML) correlates with lower levels of NKp30 and NKp46 expression on NK cells compared to healthy individuals (87–89). The gene discussed is NCR1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.